



# HHS Public Access

Author manuscript

*Biochim Biophys Acta Mol Basis Dis.* Author manuscript; available in PMC 2023 November 11.

Published in final edited form as:

*Biochim Biophys Acta Mol Basis Dis.* 2023 August ; 1869(6): 166717. doi:10.1016/j.bbadis.2023.166717.

## Insights into the regulation of cellular Mn<sup>2+</sup> homeostasis via TMEM165

Dorothee Vicogne<sup>a</sup>, Nicolas Beauval<sup>b</sup>, Zoé Durin<sup>a</sup>, Delphine Allorge<sup>b</sup>, Kateryna Kondratska<sup>c,d</sup>, Aurélien Haustrate<sup>c,d</sup>, Natasha Prevarskaya<sup>c,d</sup>, Vladimir Lupashin<sup>e</sup>, Dominique Legrand<sup>a,1</sup>, François Foulquier<sup>a,\*,1</sup>

<sup>a</sup>Univ. Lille, CNRS, UMR 8576 – UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France

<sup>b</sup>Univ. Lille, CHU Lille, Institut Pasteur de Lille, ULR 4483 - IMPECS - IMPact de l'Environnement Chimique sur la Santé humaine, F-59000 Lille, France

<sup>c</sup>Univ. Lille, INSERM U1003-PHYCEL-Physiology Cellulaire, F-59000 Lille, France

<sup>d</sup>Ion Channels Science and Therapeutics, Université de Lille, Villeneuve d'Ascq, France

<sup>e</sup>Department of Physiology and Biophysics, College of Medicine, University of Arkansas for Medical Sciences, Biomed 261-2, slot 505, 200 South Cedar St., Little Rock, AR 72205, USA

### Abstract

Golgi cation homeostasis is known to be crucial for many cellular processes including vesicular fusion events, protein secretion, as well as for the activity of Golgi glycosyltransferases and glycosidases. TMEM165 was identified in 2012 as the first cation transporter related to human glycosylation diseases, namely the Congenital Disorders of Glycosylation (CDG). Interestingly, divalent manganese (Mn) supplementation has been shown to suppress the observed glycosylation defects in TMEM165-deficient cell lines, thus suggesting that TMEM165 is involved in cellular Mn homeostasis. This paper demonstrates that the origin of the Golgi glycosylation defects arises from impaired Golgi Mn homeostasis in TMEM165-depleted cells. We show that Mn supplementation fully rescues the Mn content in the secretory pathway/organelles of TMEM165-depleted cells and hence the glycosylation process. Strong cytosolic and organellar Mn accumulations can also be observed in TMEM165- and SPCA1-depleted cells upon incubation with increasing Mn concentrations, thus demonstrating the crucial involvement of these two proteins in cellular Mn homeostasis. Interestingly, our results show that the cellular Mn

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\*Corresponding author at: Univ. Lille, CNRS, UMR 8576 – UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France. [francois.foulquier@univ-lille.fr](mailto:francois.foulquier@univ-lille.fr) (F. Foulquier).

<sup>1</sup>These authors equally contributed to this work.

Declaration of competing interest

The authors declare no conflict of interest and all authors were involved in the decision to publish and reviewed the article before submission.

CRediT authorship contribution statement

Funding acquisition: F.F. Investigation: D-V, N-B, Z.D, K-K, A.H, N-P, V.L, D.L, F.F. Supervision D.L and F.F. Validation: D-V, N-B, D.A, Z.D, K.K. Writing - review and editing: D-V, V.L, D.L and F.F.

All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bbadis.2023.166717>.

homeostasis maintenance in control cells is correlated with the presence of TMEM165 and that the Mn-detoxifying capacities of cells, through the activity of SPCA1, rely on the Mn-induced degradation mechanism of TMEM165. Finally, this paper highlights that TMEM165 is essential in secretory pathway/organelles Mn homeostasis maintenance to ensure both Golgi glycosylation enzyme activities and cytosolic Mn detoxification.

## Keywords

TMEM165; CDG; Glycosylation; SPCA1; Manganese; Golgi

---

## 1. Introduction

Divalent manganese ( $Mn^{2+}$ , Mn in the following) is a cofactor of oxidoreductases, transferases, hydrolases, lyases, isomerases and ligases necessary for many metabolic functions, energy production (plants) and anti-oxidant responses in living organisms [1]. However, although playing crucial roles in many biological pathways, Mn belongs to the category of biometals whose mechanisms governing the cellular homeostasis are poorly understood, most especially in humans [2]. This is particularly true with regard to Mn homeostasis within the secretory pathway where this metal is required for the activity of key glycosyltransferases, such as the Golgi  $\beta$ -1,4-galactosyltransferase 1, involved in glycosylation processes [3]. Before the last ten years, only one protein dedicated to Mn transport could be identified within the secretory pathway, the Golgi protein SPCA1 (ATP2C1) belonging, like the endoplasmic reticulum (ER) pumps SERCA (SERCA1/ATP2A1 (muscle specific) and SERCA2/ATP2A2 (ubiquitous)), to the P-type  $Ca^{2+}$ -ATPase family [4]. While SERCA2 is primarily a  $Ca^{2+}$  ER importer, also able to transport Mn in certain conditions, SPCA1 may bind and transport  $Ca^{2+}$  and Mn with similar affinities [5]. Actually, it was reported/hypothesized that the Mn transport function of SPCA1 better meets needs of metal detoxification from cytosol, as elevated Mn concentrations are toxic for cells, than needs for maintaining Mn Golgi homeostasis [6]. In humans, SPCA1 deficiency causes the Hailey-Hailey disease (HHD), characterized by persistent blisters and erosions of the skin mainly due to impaired  $Ca^{2+}$  homeostasis in keratinocytes [7,8].

More recently, the discovery of patients with Congenital Disorders of Glycosylation (CDG) unveiled the existence of TMEM165 as a potential key player in Golgi Mn homeostasis [9,10]. Indeed, we reported that the strong glycosylation defects detected in TMEM165-CDG patients and TMEM165 KO cell lines, affecting galactosylation in all glycosylation types (N- and O-glycosylations, glycolipids and glycosaminoglycans), may be fully rescued by  $MnCl_2$  supplementation [11–13]. This important finding, together with i) the homology of TMEM165 with other members of the UPF0016 family transporting Mn and possibly also for some of them  $Ca^{2+}$  and/or  $H^+$  in plants (PAM71, CMT1, PML3–5 from *Arabidopsis thaliana*) [14–16], cyanobacteria (SynPAM71/Mnx from *Synechocystis*) [17], and bacteria (MneA from *Vibrio cholerae*) [18], ii) the evidence that TMEM165 deficiency alters Golgi Mn homeostasis, as observed with the resistance of the Golgi Mn-sensitive GPP130 protein in TMEM165-deficient mammalian cells [19], iii) the sensitivity of TMEM165 itself to increased cytosolic Mn concentrations and its subsequent degradation in lysosomes [19] and

iv) the measurement of the Mn transport activity in *Lactococcus lactis* of both a truncated form of TMEM165 and Gdt1p, the yeast ortholog of TMEM165 [20], strongly support the assertion that TMEM165 is a Mn Golgi importer playing a key role in regulating cellular Mn homeostasis.

From these findings, it thus appears that TMEM165 and SPCA1 are important, if not unique, into the regulation of the Golgi Mn homeostasis of this metal for detoxification purposes and/or metal supply to Golgi Mn-dependent glycosyltransferases. In support to this assertion, we recently evidenced a functional link between TMEM165 and SPCA1, by demonstrating that TMEM165 abundance in cells is directly dependent on the function of SPCA1 [21]. In addition, in the pathological conditions of HHD (Hailey-Hailey Disease) where SPCA1 expression is impaired, the sensitivity of TMEM165 to elevated exogenous Mn concentrations has been found significantly increased [22]. However, the conditions governing the Golgi Mn transport activity of TMEM165 and its interplay with SPCA1 in regulating Mn cellular homeostasis are unknown so far. This paper aims to study the impact of a lack of TMEM165 on the capacity of cells to handle Mn contents within the cellular compartments, and to understand its role, together with SPCA1, in regulating secretory pathway/organelle Mn homeostasis and/or detoxification.

## 2. Materials and Methods

### 2.1. Antibodies and reagents

Anti-TMEM165 and anti- $\beta$ -actin antibodies were purchased from Sigma-Aldrich (Burlington, MA, USA), anti-LAMP2 antibody from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-SPCA1 antibodies were purchased from Sigma-Aldrich to be used in immunofluorescence staining (IF) and from Biotechnie (Minneapolis, MN, USA) to be used in western-blotting (WB), and anti-GM130 antibody was purchased from BD Biosciences (Franklin Lakes, NJ, USA). Polyclonal goat anti-rabbit or goat anti-mouse horseradish peroxidase-conjugated Igs were from Agilent Technologies (Santa Clara, CA, USA). Polyclonal goat anti-mouse or goat anti-rabbit conjugated with Alexa Fluor were purchased from Fisher Scientific (Waltham, MA, USA). Manganese (II) chloride tetrahydrate ( $\text{MnCl}_2$ ) was from Riedel-de-Haën (Seelze, Germany). Digitonin was purchased from Fisher Scientific (Waltham, USA).

### 2.2. Cell culture and manganese treatment

TMEM165 and SPCA1 KO HeLa cells were generated as previously described in Vicogne et al. [23] and Hoffmann et al. [24], respectively. Control and SPCA1 KO HeLa cells, as well as control and TMEM165 KO HeLa-GalT-GFP cells, were routinely grown in Dulbecco's Modified Eagle's Medium (DMEM) (Lonza, Basel, Switzerland) supplemented with 10 % fetal bovine serum (PAN Biotech, Germany). Control and SPCA1 KO Hap1 cells were maintained in Iscove's Modified Dulbecco's Medium (IMDM) (Fisher Scientific, Waltham, USA) supplemented with 10 % fetal bovine serum (PAN Biotech, Germany). All cell lines were maintained at 37 °C in humidity-saturated 5 %  $\text{CO}_2$  atmosphere. When used,  $\text{MnCl}_2$  was added for 16 h at increasing concentrations, ranging from 1 to 400  $\mu\text{M}$ .

## 2.3. Quantification of Mn by ICP-MS (inductively coupled plasma-mass spectrometry)

**2.3.1. Sample preparation**—After  $\text{MnCl}_2$  treatment in 12-well plates, cells were washed once with Hank's Balanced Salt Solution (HBSS) containing 1 mM of  $\text{MgCl}_2$  and 2 mM of  $\text{CaCl}_2$  and incubated with this solution for 2 h at room temperature. Next, this solution was discarded and cells were washed three times with calcium- and magnesium-free HBSS (HBSS<sup>-/-</sup>). Cells were permeabilized with HBSS<sup>-/-</sup> supplemented with digitonin (50  $\mu\text{M}$ ) for 1 min at room temperature to release cytosol content. This fraction was gently transferred into 1.5 mL tubes. Cells were immediately and quickly washed twice with HBSS<sup>-/-</sup> and these washings were added to the cytosolic fraction. To entirely lyse the cells, distilled water was added and cells were scrapped. Lysis extract was transferred into 1.5 mL tubes. This step was repeated once to assure maximal lysate recovery, added to the first extract and then sonicated for 1 min. Cytosolic fraction and lysate were stored at  $-20\text{ }^\circ\text{C}$  until further ICP-MS analysis.

**2.3.2. Mn analysis**—After separation, cytosolic and organelle samples were diluted 50 fold with 1.5 % (w/v) nitric acid (RPE analytical grade 69.5 %, Carlo Erba Reagents, Cornaredo, Italy) solution in ultrapure water (Purelab Flex, Veolia Water, Paris, France) also containing 0.1 % (v/v) Triton<sup>TM</sup>X-100 (Sigma-Aldrich, St Louis, MO, USA) and 0.2 % (v/v) butan-1-ol (VWR chemicals, Radnor, PA, USA) The analysis was performed on an ICP-MS THERMO ICAP<sup>TM</sup> Qc ICP-MS (Thermo Scientific, Waltham, MA) using kinetic energy discrimination with helium and gallium as internal standard. The lower limit of quantification was 0.2  $\mu\text{g/L}$ .

## 2.4. Western blot analysis

Cells were scrapped in Dulbecco's Phosphate Buffer (DPBS, Lonza) and then centrifuged at 6000 rpm,  $4\text{ }^\circ\text{C}$  for 10 min. Supernatant was discarded and cells were then resuspended in RIPA buffer [Tris/HCl 50 mM pH 7.9, NaCl 120 mM, NP40 0.5 %, EDTA 1 mM,  $\text{Na}_3\text{VO}_4$  1 mM, NaF 5 mM] supplemented with a protease cocktail inhibitor (Roche Diagnostics, Penzberg, Germany). Cell lysis was done by passing the cells several times through a syringe with a 26G needle. Cells were centrifuged for 30 min,  $4\text{ }^\circ\text{C}$  at 14000 rpm. Protein concentration contained in the supernatant was estimated with the micro BCA Protein Assay Kit (Fisher Scientific, Waltham, USA) according to the manufacturer's instructions. Ten  $\mu\text{g}$  of total protein lysate were mixed with NuPAGE Lithium Dodecyl Sulfate (LDS) Sample Buffer (Fisher Scientific, Waltham, USA), pH 8.4, supplemented with 4 %  $\beta$ -mercaptoethanol (Sigma-Aldrich, Saint Louis, USA). Samples were heated 10 min at  $95\text{ }^\circ\text{C}$  (excepted for TMEM165 and SPCA1), then resolved by MOPS 4 %–12 % Bis-Tris gels (Fisher Scientific, Waltham, USA). After transfer with iBlot2 Dry Blotting System (Fisher Scientific, Waltham, USA), nitrocellulose membranes were blocked using TBS (Tris Buffer Saline) containing 0.05 % Tween20 (TBS-T) and either 5 % (w/v) non-fat dried milk ( $\beta$ -actin and LAMP2 antibodies) or 5 % (w/v) bovine serum albumin (BSA) (TMEM165 and SPCA1 antibodies) for at least 1 h at room temperature (RT). Primary rabbit antibodies anti-TMEM165, mouse anti-SPCA1, mouse anti- $\beta$ -actin, and mouse anti-LAMP2 were incubated overnight at  $4\text{ }^\circ\text{C}$  in TBS-T and 5 % (w/v) BSA or 5 % (w/v) non-fat dried milk at respectively 1:1000, 1:4000, 1:10,000 and 1:3000 dilutions. After three TBS-T washes, membranes were then incubated with peroxidase-conjugated

secondary goat anti-rabbit or goat anti-mouse antibodies (used at a dilution of 1:10,000 or 1:20,000 in blocking buffer) for 1 h at RT. After five TBS-T washes, blots were developed using enhanced chemiluminescence (West Pico Plus, ThermoScientific). The images were acquired using a CCD camera (Fusion Solo, Vilbert Lourmat).

## 2.5. Immunofluorescence staining

Cells were seeded on coverslips for 24 h, washed twice in Dulbecco's Phosphate Buffer Saline (DPBS, Lonza) and fixed with 4 % paraformaldehyde (PAF) in PBS (Phosphate Buffer Saline) pH 7.4 for 30 min at room temperature. Coverslips were then washed three times with PBS and cells were permeabilized with 0.5 % Triton X-100 in PBS for 10 min before being washed three times with PBS. Coverslips were then incubated either for 2 h in BSA-Block (Candor-Bioscience, Germany) (SPCA1 antibody) or for 1 h in blocking buffer (0.2 % gelatin, 2 % bovine serum albumin, 2 % fetal bovine serum in PBS) (GM130 and TMEM165 antibodies) and then for 2 h with primary antibody diluted either at 1:100 (anti-SPCA1 and anti-GM130) or 1:300 (anti-TMEM165) in BSA-Block or blocking buffer. After 3 washings with PBS, cells were incubated for 1 h with Alexa Fluor 488-, or Alexa Fluor 568- conjugated secondary antibody (Fisher Scientific) diluted at 1:600 in BSA-Block or blocking buffer. After 3 washings with PBS, nuclei were labelled with DAPI 1:200 for 10 min and then mounted on glass slides with Mowiol. Fluorescence was detected by an inverted Zeiss LSM700 confocal microscope. Acquisitions were done using ZEN Pro2.1 Software (Zeiss, Oberkochen, Germany).

## 2.6. Statistical analysis

ANOVA was used for statistical comparison of the differences. For each analysis, experiments have been done at least in triplicates.  $p < 0.05$  were considered as significant in experiments. For each graph, \*:  $p < 0.05$ ; \*\*:  $p < 0.01$ ; \*\*\*:  $p < 0.001$ .

## 3. Results

### 3.1. The observed glycosylation defect in TMEM165 KO cells results from a defect in membrane-bound organelle Mn homeostasis

Our previous work highlighted an unexpected functional link between TMEM165 and SPCA1 with a complete loss of TMEM165 observed in SPCA1 KO cells both by immunofluorescence and western blot [19,21], as confirmed in Fig. 1 A,B. In contrast, the effect of a lack of TMEM165 on SPCA1 had never been investigated. For this, the abundance of SPCA1 was examined in TMEM165 KO cells by western blot and immunofluorescence (Fig. 1D, E). Compared to control cells, a slight decrease in SPCA1 (about 20 %) is observed in TMEM165 KO cells (Fig. 1D, E). To confirm the involvement of TMEM165 in the observed SPCA1 decrease, wt-TMEM165 was transiently expressed in TMEM165 KO cells and the stability of SPCA1 was assessed by immunofluorescence. As shown in Supplementary Fig. 1, the transient expression of wt-TMEM165 rescues the abundance of SPCA1 in the Golgi. Moreover, and interestingly, a strong Golgi glycosylation defect was associated with the lack of TMEM165 (Fig. 1F), while absolutely no Golgi glycosylation abnormalities were observed in SPCA1 KO cells as assessed by the absence of LAMP2 electrophoretic mobility (Fig. 1C). We then hypothesized that this difference

in Golgi glycosylation could arise from an impaired Golgi Mn homeostasis in TMEM165 KO cells, as previously suggested [11,12,23,25,26]. To tackle this fundamental point, Mn levels in cytosol versus intracellular compartments were assessed by using a well-known and robust methodology based on digitonin action that only permeabilizes, when used at low concentration (0.01–0.02 % (*w/v*)), the plasma membrane [27]. The digitonin cell permeabilization protocol that will be used throughout the paper is depicted in Supplementary Fig. 2. This selective permeabilization therefore releases cytosolic solutes leaving the content of intracellular compartments such as endoplasmic reticulum (ER), Golgi apparatus, mitochondria, endosomes and nucleus unchanged. *Via* this methodology, the Mn amounts in the cytosol versus intracellular compartments can then be quantified using inductively-coupled plasma mass spectrometry (ICP-MS). This was applied to TMEM165 and SPCA1 KO cells.

At the steady state (no exogenous Mn added), the cytosolic Mn content was found similar in TMEM165 KO, SPCA1 KO and control HeLa cells (Fig. 2A). Regarding the membrane-bound organelle fraction, a 10-fold decrease in Mn concentration was observed in TMEM165 KO cells compared to SPCA1 KO and control HeLa cells (Fig. 2A). Given this astonishing absence of Mn accumulation in SPCA1 KO cells, which lacks both SPCA1 and TMEM165 (Fig. 1A, B), the same experiment was performed in another cellular background, namely SPCA1 KO Hap1 cells (Supplementary Fig. 3). In SPCA1 KO Hap1 cells, 5.8- and 1.4-fold Mn increases were observed in the cytosolic and membrane-bound organelle fractions, respectively, as compared to control cells, highlighting the establishment in HeLa cells of compensatory mechanisms to maintain their Mn homeostasis.

We then focused on the very low Mn concentration observed in the membrane-bound organelle fraction of TMEM165 KO cells asking whether this decreased Mn amount would account for the observed massive Golgi glycosylation defects in TMEM165 KO cells. To tackle this question, TMEM165 KO cells were next treated with 1  $\mu\text{M}$   $\text{MnCl}_2$  for 16 h, a condition that is known to fully suppress the glycosylation defects (Fig. 2B), and Mn quantification was re-performed. In such conditions, 3.5 and 4.8-fold increases in Mn concentration can be observed in membrane-bound organelles of control and TMEM165 KO cells, respectively (Fig. 2A). Furthermore, it is interesting to note that the Mn amount observed in TMEM165 KO cells treated with 1  $\mu\text{M}$   $\text{MnCl}_2$  is close to the one observed in control cells without  $\text{MnCl}_2$  treatment. In parallel, the same treatment was applied to SPCA1 KO cells. Interestingly, whereas the control cells significantly accumulated Mn in their membrane-bound organelles, with no or little Mn accumulation in their cytosol, the SPCA1 KO cells exhibited a drastic accumulation of Mn in both cytosolic and membrane-bound organelle compartments, of the order of 4.2 and 6.6-fold respectively, as compared to control cells. This result demonstrates a clear defect in cellular Mn homeostasis maintenance in SPCA1 KO cells when only 1  $\mu\text{M}$   $\text{MnCl}_2$  was applied. Altogether these results unravel that the observed Golgi glycosylation defect in TMEM165 KO cells originates from a lack of Mn in membrane-bound organelles, most likely in the Golgi apparatus given the Golgi subcellular localization of TMEM165.

### 3.2. Both TMEM165 and SPCA1 are crucial in maintaining cytosolic and membrane-bound organelle Mn homeostasis

The previous results strongly suggest a Mn transport mechanism from the cytosol to the Golgi lumen *via* TMEM165. If correct, TMEM165 deficiency should lead to an increase of the cytosolic Mn content upon increasing MnCl<sub>2</sub> supplementation. To assess this hypothesis, control, TMEM165 and SPCA1 KO HeLa cells were first incubated with increasing moderate Mn concentrations (0 to 50 μM) for 16 h and the digitonin cell permeabilization methodology was applied to quantify the cytosolic and membrane-bound organelle Mn contents. As depicted in Fig. 3 and Supplementary Fig. 4 for statistical comparisons, no cytosolic Mn accumulation was observed in control cells, in sharp contrast with the marked increase of Mn content observed in both TMEM165 and SPCA1 KO cells incubated with increasing MnCl<sub>2</sub> concentrations from 2.5 to 50 μM. In particular, upon incubation with 25 μM MnCl<sub>2</sub>, the TMEM165 KO cells exhibited an 8.9-fold higher cytosolic Mn content than the one observed in control cells. Although the slope of cytosolic Mn accumulation is similar between TMEM165 and SPCA1 KO cells, a two-fold accumulation of Mn is seen in SPCA1 KO cells compared to TMEM165 KO cells. Since SPCA1 KO cells lack both SPCA1 and TMEM165, it may thus be deduced that both proteins participate in the efflux of Mn from the cytosol.

Regarding the membrane-bound organelle fraction, Mn concentration increased in all three cell lines but with completely different orders of magnitude (Fig. 3). In control cells, the Mn concentration raised slightly upon 1 μM Mn incubation then remained stable for increasing Mn concentrations, thus demonstrating a tight Mn homeostasis regulation of membrane-bound organelles. This contrasts with the results obtained in both TMEM165 and SPCA1 KO cells where a marked Mn concentration increase is seen (2.3 and 8.1-fold for TMEM165 KO and SPCA1 KO cells, respectively, as compared to control cells).

We then wondered what would happen for higher MnCl<sub>2</sub> concentrations (100 to 400 μM for 16 h). As shown in Fig. 4A, whereas the control cells kept their cytosolic Mn content low till 100 μM MnCl<sub>2</sub>, a 3.2-fold increase was achieved at 200 μM MnCl<sub>2</sub> and, surprisingly, a level similar to that observed in TMEM165 KO cells was reached at 400 μM MnCl<sub>2</sub> (36.5-fold increase). This obviously leads to repercussions on the membrane-bound organelle Mn content at 400 μM MnCl<sub>2</sub>, most especially that of SPCA1 KO cells lacking both SPCA1 and TMEM165 (Fig. 4A). Altogether our results indicate that, in control cells, TMEM165 is essential in regulating the cytosolic Mn homeostasis till 200 μM of exogenous MnCl<sub>2</sub>, and that above that concentration (400 μM MnCl<sub>2</sub> in our experiment), it does not seem longer functional. In order to explain this phenomenon, the stability of TMEM165 was followed. As shown in Fig. 4B, the stability of TMEM165 in control cells was found markedly decreased from 100 to 400 μM MnCl<sub>2</sub> with the presence of lighter molecular weight protein bands (down to 25 kDa) likely corresponding to degradation forms of TMEM165. This confirms our previous results demonstrating the Mn-induced degradation of TMEM165 upon MnCl<sub>2</sub> treatment and its blocking by lysosomal inhibitors [19]. Altogether these findings highlight a strong correlation between the markedly-increased accumulation of cytosolic Mn in control cells and the observed Mn-induced degradation of TMEM165.

These intriguing results prompted us to similarly evaluate the cellular Mn content in SPCA1 KO cells deficient for both SPCA1 and TMEM165. Therefore, SPCA1 KO cells were treated with MnCl<sub>2</sub> concentrations from 100 to 400 μM for 16 h and the same methodology was applied. Upon 100 μM MnCl<sub>2</sub> incubation, the SPCA1 KO cells exhibited a 16-fold higher Mn cytosolic content than the one observed in control cells but similar to that observed in TMEM165 KO cells (14.2-fold increase) (Fig. 4A). Intriguingly, the corresponding Mn amounts found in the membrane-bound organelles of SPCA1 KO cells were 11.3-fold higher than in control cells, and 3.3-fold higher than in TMEM165 KO cells. In conclusion, although no difference can be observed between TMEM165 KO and SPCA1 KO cells with regard to Mn accumulation in their cytosol, a marked difference resides in their membrane-bound organelle Mn content, about twice higher in SPCA1 KO cells than in TMEM165 KO cells.

### 3.3. SPCA1 activity is affected in TMEM165 KO cells

This observed accumulation of Mn in the cytosol but also in membrane-bound organelles of control, TMEM165 and SPCA1 KO cells upon 400 μM MnCl<sub>2</sub> treatment led us to investigate the Mn detoxification capacities of these cells. According to the literature, one way to cope with cytosolic Mn excess involves the activity of SPCA1 in a so-called detoxification pathway [6]. For assessing the detoxification capacities and for comparisons, the cells were treated with different MnCl<sub>2</sub> concentrations to reach about the same Mn contents whether in cytosol or in membrane-bound organelles. To this end, control and TMEM165 KO cells were incubated with 400 μM MnCl<sub>2</sub> and SPCA1 KO cells with 100 μM MnCl<sub>2</sub>. Cells were then washed and incubated in a free Mn medium for 3 and 6 h and subjected to our cell permeabilization methodology to evaluate and compare the kinetic of Mn detoxification in the cytosol and membrane-bound organelles. As shown in Fig. 5, the cytosolic Mn detoxification of control cells was very efficient as the initial cytosolic Mn pool decreased by 79 and 93 % after 3 and 6 h, respectively. In SPCA1 KO cells, in contrast, the cytosolic Mn detoxification occurred at a much slower rate as the initial cytosolic pool decreases by only 30 and 54 % after 3 and 6 h, respectively. Since the difference between the two curves is supposed to reflect the activity of SPCA1 in cytosolic Mn detoxification, it may be assumed that in control cells, about 50 % of the observed Mn detoxification is due to the activity of SPCA1. It is also important to note that, in this set of experiments, the contribution of TMEM165 is negligible as found absent in both control (incubated with 400 μM MnCl<sub>2</sub>) and SPCA1 KO cells. Regarding TMEM165 KO cells, the result is close to the one observed in SPCA1 KO cells, with 41 and 78 % cytosolic Mn content decreases after 3 and 6 h, respectively. Since TMEM165 is absent in 400 μM MnCl<sub>2</sub>-treated control cells as well as in TMEM165 KO cells, these results highly suggest that SPCA1's activity in detoxifying cytosolic Mn is likely altered in TMEM165 KO cells.

Concerning the Mn detoxification associated with membrane-bound organelles, our results are similar to those obtained above. A much slower detoxification is seen in SPCA1 KO cells compared to control and TMEM165 KO cells. 38 and 54 % decreases are observed for SPCA1 KO cells after 3 and 6 h, respectively, compared to 57 % and 70 % for TMEM165 KO cells and 69 % and 85 % for control cells. This suggests that only about 50 % of



the accumulating Mn in SPCA1 KO cells is mobilizable for secretion instead of 85 % for control cells.

#### 4. Discussion

TMEM165 was described in 2012 as a new gene related to human glycosylation diseases, namely Congenital Disorders of Glycosylation (CDG) [9]. Since then, many achievements were done to decipher the function of TMEM165 in the etiology of the glycosylation deficiency. Our results highlighted that the singularity of TMEM165 deficiency lies in the general observed glycosylation defects, as synthesis of N- and O-linked glycans, glycosphingolipids and glycosaminoglycans (GAGs) was shown to be altered [9,12,26,28,29]. Although TMEM165 deficiency can affect most of the Golgi glycosylation reactions, the galactosylation reaction was found severely altered in all the aforementioned different glycosylation types. As galactosylation is fundamental in lactose synthesis, we postulated in 2012 that TMEM165 should be crucial in such synthesis. This was demonstrated in 2014 and 2019 by Reinhardt and Snyder. They both observed strong milk quality defects with lower lactose, calcium and manganese levels in Tmem165 knockout mice [30,31]. These results led to a model where TMEM165 would import both cytosolic  $Mn^{2+}$  and  $Ca^{2+}$  to the Golgi in exchange for  $H^+$  as over acidification of the Golgi apparatus and acidic compartments in TMEM165-depleted cells was evidenced [32,33]. The function of TMEM165 in regulating cellular Mn homeostasis was figured out much later from many observations, and particularly from the fact that all the observed TMEM165-associated glycosylation defects could fully be suppressed by tiny amounts of exogenous  $MnCl_2$  [11,12,23,25]. This observation has been the keystone to postulate that TMEM165 could be a Mn transporter crucial to provide Mn into the Golgi, itself conducive to the activities of the Mn-dependent glycosylation enzymes present in that organelle. Together with mitochondria and nucleus, Golgi is known to constitute an important membrane-bound organelle for Mn storage [34–36]. Many pumps and transporters are involved in regulating Mn homeostasis along the secretory pathway, in post-Golgi vesicles and also at the plasma membrane. For example, human Zn transporters such as SLC39A8, SLC30A10 and SLC39A14 have been shown to contribute to cellular Mn homeostasis but most of these transporters are non-specific and can transport other cationic biometals [37–41]. At the steady state, the observed Mn concentration in one specific compartment not only results from the combined activities of the different transporters and pumps but also of the concentration of other metals. Although crucial in our understanding, the impact of a lack of TMEM165 on cellular Mn homeostasis had never been investigated, primarily caused by the absence of either truly specific and/or sensitive Mn sensors or practical and/or cost-effective biophysical methods, unlike radioactive trace assays or the synchrotron X-ray fluorescence nanoimaging [42,43]. The  $Ca^{2+}$  fluorescent indicator Fura-2 AM is the most used Mn sensor as it can measure intracellular Mn by quenching, but only in relative amounts [44]. Furthermore, Fura-2 AM can only cross the plasma membrane, not the membranes of organelles. Interestingly, a new method, called MESMER (Manganese-Extracting Small Molecule Estimation Route) was recently developed [45]. Based on Mn-induced Fura-2 quenching, it uses a selective Mn ionophore called MESM (Manganese-Extracting Small Molecule) enabling non-lethal

quantification of cellular Mn. However, it is unclear whether MESM crosses intracellular membranes [45] and MESMER thus does not constitute a suitable method.

In this paper, we used a digitonin cell permeabilization based approach, coupled to ICP-MS analysis, to investigate and quantify the differential amounts of Mn in the cytosol and membrane-bound organelles of control, SPCA1 and TMEM165 KO cells.

We first show that, when cells were not supplemented with  $\text{MnCl}_2$ , the Mn amount in membrane-bound organelles was 4-fold decreased in TMEM165 KO cells compared to control or SPCA1 KO cells. Given the Golgi localization of TMEM165, it may be assumed that the observed Mn decrease most likely affects the Golgi compartment then explaining the origin of the observed glycosylation deficiencies, while demonstrating a major role of TMEM165 in the maintenance of Golgi Mn homeostasis. Interestingly, the supplementation of the culture medium with  $1 \mu\text{M MnCl}_2$  was sufficient to restore the Mn level associated to membrane-bound organelles to the one initially seen in control cells in absence of exogenous Mn. This result perfectly correlates with the reappearance of fully-glycosylated LAMP2 protein forms observed following supplementation of the culture medium with  $1 \mu\text{M MnCl}_2$ , and hence strongly supports a functional role of TMEM165 in the maintenance of the Mn homeostasis in membrane-bound organelles, most likely in the Golgi. It is important to note that the same treatment in SPCA1 KO cells, which lack both SPCA1 and TMEM165, leads to a sharp increase of Mn in both cytosol and membrane-bound organelles, somehow demonstrating the fundamental importance of SPCA1, in addition to TMEM165, in regulating cellular Mn homeostasis upon mild  $\text{MnCl}_2$  supplementation.

The question on how Mn could reach the Golgi lumen and rescue the glycosylation in absence of TMEM165 particularly caught our attention and was tackled in our previous study [25]. We indeed revealed that the Mn-induced N-glycosylation rescue in TMEM165 KO HEK cells is dependent on the Mn pumping activity of ER SERCA pumps (Fig. 6). Once pumped in the ER, we can reasonably hypothesized that this Mn is redistributed into the Golgi apparatus presumably *via* vesicular trafficking [25]. This concept is fully in line with the work of Kaufman et al. [46] arguing that the requirement for Mn for oligosaccharide addition within the secretory pathway is sensitive to thapsigargin, an inhibitor of SERCA pumps.

Another very important result is the crucial involvement of both TMEM165 and SPCA1 in the regulation of the cytosolic and membrane-bound organelle Mn homeostasis, as increasing exogenous  $\text{MnCl}_2$  concentrations led to a markedly increased amount of Mn in the cytosol and membrane-bound organelles of TMEM165 KO cells and foremost SPCA1 KO cells lacking both SPCA1 and TMEM165. Indeed, while control cells can fully regulate their cellular Mn homeostasis upon  $\text{MnCl}_2$  supplementation up to  $100 \mu\text{M}$ , the lack of either TMEM165 or both SPCA1 and TMEM165 leads to a sharp accumulation of Mn in both cytosol and membrane-bound organelles. Whatever the extracellular Mn concentration applied, the observed Mn accumulation was always found higher in SPCA1 KO cells than in TMEM165 KO cells that is somehow logical if we consider the lack of TMEM165 in SPCA1 KO cells. This demonstrates that TMEM165 and SPCA1 work together in preventing cytosolic Mn accumulation. How then to explain the observed sharp

accumulation of Mn in membrane-bound organelles in SPCA1 and TMEM165 KO cells? Analyzing the control cells enables us to see a much higher Mn accumulation in membrane-bound organelles than in cytosol, thus suggesting that membrane-bound organelles may play the role of reservoir to keep the cytosolic Mn content low. Therefore, we can hypothesize that the observed cytosolic Mn accumulation in SPCA1 and TMEM165 KO cells upon supplementation with increasing extracellular  $\text{MnCl}_2$  concentrations leads to the fueling of different reservoirs within these cells, then explaining the observed Mn increase in membrane-bound organelles. The pulse-chase methodology interestingly shows that, in SPCA1 KO cells, 50 % of the accumulating Mn cannot be extruded from the cell, going to 30 % for TMEM165 KO cells and only 10 % for control cells. This thus suggests that in SPCA1 KO cells, which also lack TMEM165, most of the accumulating Mn redistributes in other subcellular compartments than those from the secretory pathway, likely mitochondria and/or nucleus.

Another last very surprising result is that control cells exhibit Mn contents similar to that of TMEM165-deficient cells upon incubation with  $\text{MnCl}_2$  concentrations reaching 400  $\mu\text{M}$ . Actually, our previous work showed that for similar  $\text{MnCl}_2$  concentrations, TMEM165 was targeted to lysosomes for degradation [19]. Here, we intriguingly show that the exogenous Mn-induced instability of TMEM165 correlates with the markedly-increased amounts of Mn in control cells, in both cytosol and membrane-bound organelles. This finding raises a number of questions about the functionality of SPCA1 upon 400  $\mu\text{M}$   $\text{MnCl}_2$  treatment, whether in control or TMEM165 KO cells. In human cells, it is indeed well known that one way to cope with cytosolic Mn excess involves SPCA1, an ATPase pump able to import Mn into the Golgi lumen for its removal [6]. Two main hypothesis can be raised to explain the observed Mn accumulation in control cells upon 400  $\mu\text{M}$   $\text{MnCl}_2$ : (i) TMEM165 itself is involved in the detoxification of cytosolic Mn excess upon  $\text{MnCl}_2$  exposure and/or (ii) the absence of TMEM165 impacts SPCA1's function. In support to the second hypothesis, our previous works highlighted a functional link between TMEM165 and SPCA1 [21,22]. We indeed demonstrated that the protein expression level and Golgi subcellular localization of TMEM165 are dependent on SPCA1's function to import cytosolic Mn into the Golgi lumen. A lack of SPCA1 results in cytosolic Mn accumulation, itself causing a specific targeting of TMEM165 to lysosomes for degradation. This result somehow argues that SPCA1 is active in detoxifying Mn in control cells, and that the sole Mn pumping activity of TMEM165, if any, is not sufficient to decrease the accumulating cytosolic Mn. This reinforces the hypothesis that the absence of TMEM165 could impact SPCA1's function. To tackle this point, we evaluated the kinetic of cytosolic Mn detoxification in control cells, TMEM165 KO and SPCA1 KO cells. Whereas the cytosolic Mn decreased rapidly in control cells, TMEM165 KO cells exhibited a slower rate, even though faster than the one observed in SPCA1 KO cells. Although SPCA1 is slightly decreased in TMEM165 KO cells, this difference in the slopes suggests that the function of SPCA1 may be altered in absence of TMEM165. It is also important to note that a strong difference is observed in cytosolic Mn decrease between control and TMEM165 KO cells upon  $\text{MnCl}_2$  exposure, although TMEM165 is absent in control cells at these exogenous Mn concentrations. The difference could correspond to the impact of the Mn-induced degradation of TMEM165 caused by SPCA1 activation. Taken as a whole, these results suggest that the degradation of TMEM165

could be a prerequisite in activating SPCA1 in Mn detoxification. For low extracellular Mn concentrations, it is possible that TMEM165 plays the dual function of maintaining the Golgi Mn homeostasis, necessary for Mn-dependent processes such as glycosylation, as well as detoxifying the cytosol from Mn accumulation. For higher extracellular Mn concentrations, we can imagine that SPCA1 is turned on to speed up the detoxification and this requires TMEM165 degradation (Fig. 6). In absence of TMEM165, SPCA1 could simply be less active in detoxifying Mn as pumping  $\text{Ca}^{2+}$ . This hypothesis is perfectly in line with our previous results on GPP130, another Mn-sensitive protein [47]. Initially, it has been demonstrated by us and others that the Mn-induced GPP130 degradation is linked to the functionality of SPCA1 in pumping Mn [11,21,48]. In TMEM165 KO cells, we always observed that the Mn-induced degradation of GPP130 upon  $\text{MnCl}_2$  treatment was strongly altered bringing us to postulate that TMEM165 could contribute to import Mn from the cytosol to the Golgi lumen [11]. In the light of our results, it could well rather be due to a lack of SPCA1 activity in TMEM165 KO cells. It is also important to note that the estimated cytosolic Mn concentration of HeLa cells without  $\text{MnCl}_2$  supplementation, deduced from our ICP-MS measurements and in accordance with estimates of other authors on brain cells [45,49], is close to 10  $\mu\text{M}$ . Hence, in comparison to  $\text{Ca}^{2+}$  whose cytosolic concentration is around 0.1  $\mu\text{M}$ , the cytosol contains about 100 times more  $\text{Mn}^{2+}$  than  $\text{Ca}^{2+}$ ! Given the similar  $K_m$  for  $\text{Mn}^{2+}$  and  $\text{Ca}^{2+}$  regarding SPCA1, in the submicromolar range [5,50] suggests that at low ion availability the relative  $\text{Ca}^{2+}$  and  $\text{Mn}^{2+}$  concentrations will determine which ion will be transported by SPCA1. One can asks how SPCA1 can then efficiently transports  $\text{Ca}^{2+}$  in the Golgi compartment. This could only be envisaged by a very tight regulation of SPCA1 likely via TMEM165.

Altogether our results suggest that TMEM165 would act both in cytosolic Mn accumulation and in maintaining secretory pathway/organelle Mn concentration for Golgi glycosylation enzymes activities. This would allow SPCA1 to maintain TGN  $\text{Ca}^{2+}$  homeostasis which is critical for many Golgi functions. For exogenous Mn concentration above 200  $\mu\text{M}$ , TMEM165 would be degraded to “turn on” SPCA1 in the Mn detoxification pathway (Fig. 6).

In conclusion, this paper for the first time brings the evidence on the crucial role of TMEM165 in regulating both cytosolic and membrane-bound organelle Mn homeostasis. It also highlights the functional interplay between TMEM165 and SPCA1 in preventing cytosolic Mn accumulation and eventually, we proved that the Golgi glycosylation defect observed in TMEM165 KO cells correlates with the decrease of Mn in secretory pathway/organelles.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We deeply thank Hans-Heinrich Hoffmann and Charles M Rice for kindly providing the SPCA1 knockout cells. We acknowledge the access to the BICeL-UMS2014-US41 platform. The authors also warmly thank the technical team of the Toxicology Laboratory of the Lille University Hospital for the manganese analysis.

## Funding

This work was supported by the ANR ENIGMnCA (ANR-21-CE14-0049-01) to F.F and by the “Centre National de la Recherche Scientifique” (CNRS).

## Data availability


Data will be made available on request.

## References

- [1]. Tuschl K, Mills PB, Clayton PT, Manganese and the brain, *Int. Rev. Neurobiol.* 110 (2013) 277–312. [PubMed: 24209443]
- [2]. Foulquier F, Legrand D, Biometals and glycosylation in humans: congenital disorders of glycosylation shed lights into the crucial role of golgi manganese homeostasis, *Biochim. Biophys. Acta Gen. Subj.* 1864 (2020), 129674. [PubMed: 32599014]
- [3]. Ramakrishnan B, Boeggeman E, Ramasamy V, Qasba PK, Structure and catalytic cycle of beta-1,4-galactosyltransferase, *Curr. Opin. Struct. Biol.* 14 (2004) 593–600. [PubMed: 15465321]
- [4]. Palmgren MG, Nissen P, P-type ATPases, *Annu. Rev. Biophys.* 40 (2011) 243–266. [PubMed: 21351879]
- [5]. Chen J, et al. , An N-terminal Ca<sup>2+</sup>-binding motif regulates the secretory pathway Ca<sup>2+</sup>/Mn<sup>2+</sup>-transport ATPase SPCA1, *J. Biol. Chem.* 294 (2019) 7878–7891. [PubMed: 30923126]
- [6]. Leitch S, et al. , Vesicular distribution of secretory pathway Ca<sup>2+</sup>-ATPase isoform 1 and a role in manganese detoxification in liver-derived polarized cells, *Biometals* 24 (2011) 159–170. [PubMed: 20981470]
- [7]. Hu Z, et al. , Mutations in ATP2C1, encoding a calcium pump, cause Hailey-Hailey disease, *Nat. Genet.* 24 (2000) 61–65. [PubMed: 10615129]
- [8]. Sudbrak R, et al. , Hailey-Hailey disease is caused by mutations in ATP2C1 encoding a novel Ca(2+) pump, *Hum. Mol. Genet.* 9 (2000) 1131–1140. [PubMed: 10767338]
- [9]. Foulquier F, et al. , TMEM165 deficiency causes a congenital disorder of glycosylation, *Am. J. Hum. Genet.* 91 (2012) 15–26. [PubMed: 22683087]
- [10]. Zeevaert R, et al., Bone dysplasia as a key feature in three patients with a novel congenital disorder of glycosylation (CDG) type II due to a deep intronic splice mutation in TMEM165, in: Zschocke J, Gibson KM, Brown G, Morava E, Peters (Eds.), *JIMD Reports - Case and Research Reports*, 2012/5, 8, Springer, Berlin Heidelberg, 2012, pp. 145–152.
- [11]. Potelle S, et al. , Glycosylation abnormalities in Gdt1p/TMEM165 deficient cells result from a defect in golgi manganese homeostasis, *Hum. Mol. Genet.* 25 (2016) 1489–1500. [PubMed: 27008884]
- [12]. Morelle W, et al. , Galactose supplementation in patients with TMEM165-CDG rescues the glycosylation defects, *J. Clin. Endocrinol. Metab.* 102 (2017) 1375–1386. [PubMed: 28323990]
- [13]. Durin Z, et al. , Differential effects of D-galactose supplementation on golgi glycosylation defects in TMEM165 deficiency, *Front. Cell Dev. Biol.* 10 (2022), 903953. [PubMed: 35693943]
- [14]. Schneider A, et al. , The evolutionarily conserved protein PHOTOSYNTHESIS AFFECTED MUTANT71 is required for efficient manganese uptake at the thylakoid membrane in Arabidopsis, *Plant Cell* 28 (2016) 892–910. [PubMed: 27020959]
- [15]. Eisenhut M, et al. , The plastid envelope CHLOROPLAST MANGANESE TRANSPORTER1 is essential for manganese homeostasis in arabidopsis, *Mol. Plant* 11 (2018) 955–969. [PubMed: 29734002]
- [16]. Hoecker N, Honke A, Frey K, Leister D, Schneider A, Homologous proteins of the manganese transporter PAM71 are localized in the golgi apparatus and endoplasmic reticulum, *Plants (Basel)* 9 (2020).
- [17]. Gandini C, Schmidt SB, Husted S, Schneider A, Leister D, The transporter SynPAM71 is located in the plasma membrane and thylakoids, and mediates manganese tolerance in synechocystis PCC6803, *New Phytol* 215 (2017) 256–268. [PubMed: 28318016]

- [18]. Brandenburg F, et al. , The synechocystis manganese exporter mnx is essential for manganese homeostasis in cyanobacteria, *Plant Physiol.* 173 (2017) 1798–1810. [PubMed: 28153926]
- [19]. Potelle S, et al. , Manganese-induced turnover of TMEM165, *Biochem. J.* 474 (2017) 1481–1493. [PubMed: 28270545]
- [20]. Stribny J, Thines L, Deschamps A, Goffin P, Morsomme P, The human golgi protein TMEM165 transports calcium and manganese in yeast and bacterial cells, *J. Biol. Chem.* 295 (2020) 3865–3874. [PubMed: 32047108]
- [21]. Lebredonchel E, et al. , Investigating the functional link between TMEM165 and SPCA1, *Biochem. J.* 476 (2019) 3281–3293. [PubMed: 31652305]
- [22]. Roy A-S, et al. , SPCA1 governs the stability of TMEM165 in Hailey-Hailey disease, *Biochimie* 174 (2020) 159–170. [PubMed: 32335229]
- [23]. Vicogne D, et al. , Fetal bovine serum impacts the observed N-glycosylation defects in TMEM165 KO HEK cells, *J. Inherit. Metab. Dis.* 43 (2019) 357–366. [PubMed: 31415112]
- [24]. Hoffmann H-H, et al. , Diverse viruses require the calcium transporter SPCA1 for maturation and spread, *Cell Host Microbe* 22 (2017) 460–470.e5. [PubMed: 29024641]
- [25]. Houdou M, et al. , Involvement of thapsigargin and cyclopiazonic acid-sensitive pumps in the rescue of TMEM165-associated glycosylation defects by Mn<sup>2+</sup>, *FASEB J.* 33 (2018) 2669–2679. [PubMed: 30307768]
- [26]. Khan S, Sbeity M, Foulquier F, Barré L, Ouzzine M, TMEM165 a new player in proteoglycan synthesis: loss of TMEM165 impairs elongation of chondroitin- and heparan-sulfate glycosaminoglycan chains of proteoglycans and triggers early chondrocyte differentiation and hypertrophy, *Cell Death Dis.* 13 (2021) 1–14. [PubMed: 34911928]
- [27]. Niklas J, Melnyk A, Yuan Y, Heinzle E, Selective permeabilization for the high-throughput measurement of compartmented enzyme activities in mammalian cells, *Anal. Biochem.* 416 (2011) 218–227. [PubMed: 21683676]
- [28]. Schulte Althoff S, et al. , TMEM165 deficiency: postnatal changes in glycosylation, *JIMD Rep* 26 (2015) 21–29. [PubMed: 26238249]
- [29]. Bammens R, et al. , Abnormal cartilage development and altered N-glycosylation in Tmem165-deficient zebrafish mirrors the phenotypes associated with TMEM165-CDG, *Glycobiology* 25 (2015) 669–682. [PubMed: 25609749]
- [30]. Reinhardt TA, Lippolis JD, Sacco RE, The Ca<sup>2+</sup>/H<sup>+</sup> antiporter TMEM165 expression, localization in the developing, lactating and involuting mammary gland parallels the secretory pathway Ca<sup>2+</sup> ATPase (SPCA1), *Biochem. Biophys. Res. Commun.* 445 (2014) 417–421. [PubMed: 24530912]
- [31]. Snyder NA, Palmer MV, Reinhardt TA, Cunningham KW, Milk biosynthesis requires the golgi cation exchanger TMEM165, *J. Biol. Chem.* 294 (2019) 3181–3191. [PubMed: 30622138]
- [32]. Wang H, et al. , In situ fluorescent and photoacoustic imaging of golgi pH to elucidate the function of transmembrane protein 165, *Anal. Chem.* 92 (2020) 3103–3110. [PubMed: 32003966]
- [33]. Demaegd D, et al. , Newly characterized golgi-localized family of proteins is involved in calcium and pH homeostasis in yeast and human cells, *Proc. Natl. Acad. Sci. U. S. A.* 110 (2013) 6859–6864. [PubMed: 23569283]
- [34]. Das S, et al. , Manganese mapping using a fluorescent Mn<sup>2+</sup> sensor and nanosynchrotron X-ray fluorescence reveals the role of the golgi apparatus as a manganese storage site, *Inorg. Chem.* 58 (2019) 13724–13732. [PubMed: 31503472]
- [35]. Gavin CE, Gunter KK, Gunter TE, Manganese and calcium transport in mitochondria: implications for manganese toxicity, *Neurotoxicology* 20 (1999) 445–453. [PubMed: 10385903]
- [36]. Kalia K, Jiang W, Zheng W, Manganese accumulates primarily in nuclei of cultured brain cells, *Neurotoxicology* 29 (2008) 466–470. [PubMed: 18400301]
- [37]. Bosomworth HJ, Thornton JK, Coneyworth LJ, Ford D, Valentine RA, Efflux function, tissue-specific expression and intracellular trafficking of the zn transporter ZnT10 indicate roles in adult zn homeostasis, *Metallomics* 4 (2012) 771–779. [PubMed: 22706290]


- [38]. Taylor KM, Morgan HE, Johnson A, Nicholson RI, Structure-function analysis of a novel member of the LIV-1 subfamily of zinc transporters, ZIP14, FEBS Lett. 579 (2005) 427–432. [PubMed: 15642354]
- [39]. Nebert DW, Liu Z, SLC39A8 gene encoding a metal ion transporter: discovery and bench to bedside, Hum Genomics 13 (2019) 51. [PubMed: 31521203]
- [40]. Girijashanker K, et al. , Slc39a14 gene encodes ZIP14, a metal/bicarbonate symporter: similarities to the ZIP8 transporter, Mol. Pharmacol. 73 (2008) 1413–1423. [PubMed: 18270315]
- [41]. Liu Z, et al. , Cd<sup>2+</sup> versus Zn<sup>2+</sup> uptake by the ZIP8 HCO<sub>3</sub><sup>-</sup>-dependent symporter: kinetics, electrogenicity and trafficking, Biochem. Biophys. Res. Commun. 365 (2008) 814–820. [PubMed: 18037372]
- [42]. Carmona A, et al. , Manganese accumulates within golgi apparatus in dopaminergic cells as revealed by synchrotron X-ray fluorescence nanoimaging, ACS Chem. Neurosci. 1 (2010) 194–203. [PubMed: 22778823]
- [43]. Das S, et al. , Manganese mapping using a fluorescent Mn<sup>2+</sup> sensor and nanosynchrotron X-ray fluorescence reveals the role of the golgi apparatus as a manganese storage site, Inorg. Chem. 58 (2019) 13724–13732. [PubMed: 31503472]
- [44]. Kwakye GF, Li D, Kabobel OA, Bowman AB, Cellular fura-2 manganese extraction assay (CFMEA), Curr. Protoc. Toxicol. 12 (2011). Unit12.18.
- [45]. Horning KJ, et al. , Identification of a selective manganese ionophore that enables nonlethal quantification of cellular manganese, J. Biol. Chem. 295 (2020) 3875–3890. [PubMed: 32047113]
- [46]. Kaufman RJ, Swaroop M, Murtha-Riel P, Depletion of manganese within the secretory pathway inhibits O-linked glycosylation in mammalian cells, Biochemistry 33 (1994) 9813–9819. [PubMed: 8060988]
- [47]. Masuda M, Braun-Sommargren M, Crooks D, Smith DR, Golgi phosphoprotein 4 (GPP130) is a sensitive and selective cellular target of manganese exposure, Synapse 67 (2013) 205–215. [PubMed: 23280773]
- [48]. Mukhopadhyay S, Linstedt AD, Identification of a gain-of-function mutation in a golgi P-type ATPase that enhances Mn<sup>2+</sup> efflux and protects against toxicity, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 858–863. [PubMed: 21187401]
- [49]. Bowman AB, Aschner M, Considerations on manganese (Mn) treatments for in vitro studies, Neurotoxicology 41 (2014) 141–142. [PubMed: 24509086]
- [50]. Van Baelen K, Vanoevelen J, Missiaen L, Raeymaekers L, Wuytack F, The golgi PMR1 P-type ATPase of *Caenorhabditis elegans*. Identification of the gene and demonstration of calcium and manganese transport, J. Biol. Chem. 276 (2001) 10683–10691. [PubMed: 11134055]

**Fig. 1.**

TMEM165 and SPCA1 expression in SPCA1 and TMEM165 KO cells, respectively.

A. Subcellular localization and abundance of TMEM165 and GM130 in HeLa control and SPCA1 KO cells. B. Expression of TMEM165 and SPCA1 in HeLa control cells versus SPCA1 KO cells. Total cell lysates were prepared, subjected to SDS-PAGE and immunoblotted with the indicated antibodies. C. Expression and gel mobility of LAMP2 in HeLa control cells versus SPCA1 KO cells. D. Subcellular localization and abundance of TMEM165 and SPCA1 in HeLa control and TMEM165 KO cells. E. Expression of TMEM165 and SPCA1 in HeLa control cells versus TMEM165 KO cells. Total cell lysates were prepared, subjected to SDS-PAGE and immunoblotted with the indicated antibodies. F. Expression and gel mobility of LAMP2 in HeLa control cells versus TMEM165 KO cells.



**Fig. 2.**

Golgi glycosylation defects in TMEM165 KO cells arise from a lack of manganese in membrane-bound organelles. Comparison of the steady state Mn contents in cytosol and membrane-bound organelles in control, SPCA1 and TMEM165 KO HeLa cells, without and with 1 μM MnCl<sub>2</sub> supplementation.

A. Cytosol and membrane-bound organelle Mn contents in control, SPCA1 KO and TMEM165 KO HeLa cells without and with 1 μM MnCl<sub>2</sub> supplementation. Cells were permeabilized with digitonin, as described in Materials and Methods, to release the Mn cytosolic solutes while leaving the intracellular compartments intact. The graphs show the quantification of Mn contents of the three cell lines, supplemented or not with 1 μM MnCl<sub>2</sub> for 16 h, within their cytosol (Cytosol – left panel) and membrane-bound organelles (Organelles – right panel) using quantification by inductively-coupled plasma mass spectrometry (ICP-MS), as described in Materials and Methods. Data are means ± standard deviation (SD) ( $n = 3$ ). Statistical significance was determined by two-way ANOVA with multiple comparisons and is denoted by the following: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ . B. Expression of LAMP2, used as a glycosylation reporter, in TMEM165 KO HeLa cells without and with 1 μM MnCl<sub>2</sub> supplementation for 16 h.


Western-blot and immunostaining of LAMP2 were performed as described in Materials and Methods. The vertical bars indicate the electrophoretic migration distances corresponding to the fully- (Fully-glyc.) and under- (Under-glyc.) glycosylated forms of LAMP2.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




**Fig. 3.**

TMEM165 and SPCA1 are crucial in regulating cellular Mn homeostasis. Effects of MnCl<sub>2</sub> supplementation up to 50 μM on the cytosol versus organelles steady state Mn contents of HeLa cells deficient or not in SPCA1 and/or TMEM165.


Cells were permeabilized with digitonin, as described in Materials and Methods, to release the Mn cytosolic solutes while leaving the intracellular compartments intact. The graphs show the quantification of Mn contents of the three cell lines, supplemented or not with different increasing MnCl<sub>2</sub> concentrations (1, 2.5, 5, 25 and 50 μM) for 16 h, within their cytosol (Cytosol – left panel) and membrane-bound organelles (Organelles – right panel) using ICP-MS, as described in Materials and Methods. Data are means ± SD (*n* = 3).

Statistical significance was determined by one-way ANOVA with multiple comparisons and is denoted by the following: \*, *p* < 0.05; \*\*, *p* < 0.01; \*\*\*, *p* < 0.001.

**Fig. 4.**

Cellular Mn homeostasis maintenance in control cells requires the presence of TMEM165. Impacts of high MnCl<sub>2</sub> supplementation on the cytosol versus organelle steady state Mn contents of control, SPCA1 KO and TMEM165 KO HeLa cells.


A. Cytosol and membrane-bound organelle Mn contents in control, SPCA1 KO and TMEM165 KO HeLa cells supplemented or not with 100, 200 and 400 μM MnCl<sub>2</sub>. Cells were permeabilized with digitonin, as described in Materials and Methods, to release the Mn cytosolic solutes while leaving the intracellular compartments intact. The graphs show the quantification of Mn contents of the three cell lines, supplemented or not with different MnCl<sub>2</sub> concentrations for 16 h, within their cytosol (Cytosol – left panel) and membrane-bound organelles (Organelles – right panel) using ICP-MS, as described in Materials and Methods. Data are means ± SD ( $n = 3$ ). Statistical significance was determined by one-way ANOVA with multiple comparisons and is denoted by the following: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ . B. TMEM165 stability in control HeLa cells supplemented or not with 100, 200 and 400 μM MnCl<sub>2</sub>. The Western-blot shows the presence and electrophoretic migration pattern of TMEM165 within control HeLa cells supplemented or not with MnCl<sub>2</sub> for 16 h, as described in Materials and Methods. TMEM165 KO HeLa cells submitted to the same conditions are used as TMEM165 protein expression controls. The vertical bars indicate the increasing presence of TMEM165 degradation forms upon Mn supplementation of HeLa cells from 200 to 400 μM MnCl<sub>2</sub>. The graph on the right depicts the quantification of relative TMEM165 protein expression in control cells upon MnCl<sub>2</sub> treatment. Data are means ± SD ( $n = 3$ ).



**Fig. 5.**

Mn detoxification is altered in SPCA1 KO and TMEM165 KO HeLa cells.

Control and TMEM165 KO HeLa cells were incubated with 400  $\mu\text{M}$   $\text{MnCl}_2$  for 16 h, and SPCA1 KO HeLa cells with 100  $\mu\text{M}$   $\text{MnCl}_2$  for 16 h. Cells were then washed and incubated for 3 and 6 h in a  $\text{MnCl}_2$  –free medium. The graphs show the quantification of the cytosol versus organelles steady state Mn contents of control, SPCA1 KO and TMEM165 KO HeLa cells using ICP-MS. Data are means  $\pm$  SD ( $n = 3$ ). Statistical significance was determined by one-way ANOVA with multiple comparisons and is denoted by the following: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ .



**Fig. 6.** Cellular model for TMEM165 and SPCA1's functioning.

A. In absence of TMEM165, the cytosolic Mn is not efficiently transported into the Golgi apparatus (GA). As most of the Golgi glycosyltransferases require Mn as cofactor, general Golgi glycosylation defects are observed. B. Exogenous  $\text{MnCl}_2$  supplementation in TMEM165 KO cells rescues the Golgi glycosylation defects. In absence of TMEM165, the cytosolic Mn accumulation is pumped by thapsigargin (TG)-sensitive pumps, likely ER Serca pumps. The redistribution of Mn to the Golgi allows the functioning of glycosylation

enzymes. C. Under moderate exogenous Mn concentrations (0–200  $\mu\text{M}$ ), TMEM165 would play a crucial role in both detoxifying accumulating cytosolic Mn and bringing Mn inside the Golgi lumen to sustain the activities of glycosyltransferases. This would allow the function of SPCA1 in  $\text{Ca}^{2+}$  pumping. D. Under exogenous Mn concentrations higher than 200  $\mu\text{M}$ , TMEM165 would be degraded to “turn on” SPCA1 in the Mn detoxification pathway.